Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.52 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373512 | 0.95 | APP (1.00) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL5790883 | 0.95 | APP (0.81) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL3942347 | 0.91 | APP (0.92) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL4990072 | 0.89 | APP (0.89) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1371389 | 0.84 | APP (0.80) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1374640 | 0.83 | APP (0.79) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1371930 | 0.82 | APP (0.82) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1374496 | 0.81 | APP (1.00) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1371328 | 0.79 | CYP3A4 (0.79) | APPCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL1373499 | 0.78 | APP (1.00) | APPCYP2C9CYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046119-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | Myriad Genetics, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008006099-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 29/4885CYP2C9 1156/4885CYP2C19 630/4885 |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 21/4885CYP2C9 1035/4885CYP2C19 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.